Reset

Pipeline

Phase 1

Phase 2

Phase 3


BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK Inhibitor)
Hematology

B-cell lymphoid malignancies

BGB-11417 (Bcl-2 inhibitor) monotherapy
Hematology

Mature B-cell malignancies

ME-401 (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab
Hematology

CLL/SLL and B-cell NHL

Tislelizumab (anti-PD-1)
Hematology

R/R cHL

R/R cHL

R/R mature T- and NK-cell neoplasms

Zanubrutinib
Hematology

1L and R/R WM

R/R CLL/SLL

B-cell lymphoid malignancies

B-cell lymphoid malignancies

Previously treated B-cell lymphoid malignancies

R/R MZL

B-cell lymphoid malignancies

Zanubrutinib + Lenalidomide +/- Rituximab
Hematology

R/R DLBCL

Zanubrutinib + Obinutuzumab
Hematology

R/R FL

B-cell lymphoid malignancies

Zanubrutinib + Rituximab
Hematology

1L MCL

Zanubrutinib +/– Venetoclax
Hematology

1L CLL/SLL

BGB-3245 (BRAF inhibitor)
Solid Tumor

Advanced solid tumors with B-RAF mutations

Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)
Solid Tumor

Advanced solid tumors

Pamiparib (PARP 1/2 inhibitor)
Solid Tumor

2L/3L maintenance platinum-sensitive OC

1L maintenance platinum-sensitive GC

Advanced OC and TNBC

BRCA+ and HER2– BC

Pamiparib + Temozolomide
Solid Tumor

Advanced solid tumors

Tislelizumab (anti-PD-1)
Solid Tumor

1L HCC

2L advanced ESCC

2L/3L NSCLC

Advanced UBC

Previously treated advanced MSI-high or dMMR solid tumors

Previously treated unresectable HCC

Advanced solid tumors

Tislelizumab + BGB-10188 (PI3Kδ inhibitor)
Solid Tumor

Advanced solid tumors

Tislelizumab + BGB-15025 (HPK1 inhibitor)
Solid Tumor

Advanced solid tumors

Tislelizumab + BGB-A333 (anti-PD-L1)
Solid Tumor

Advanced solid tumors

Tislelizumab + BGB-A425 (anti-TIM-3)
Solid Tumor

Advanced solid tumors

Tislelizumab + BGB-A445 (anti-OX40)
Solid Tumor

Advanced solid tumors

Tislelizumab + Chemoradiotherapy
Solid Tumor

Localized ESCC

Tislelizumab + Chemotherapy
Solid Tumor

1L advanced ESCC

1L advanced nasopharyngeal cancer

1L advanced UBC

1L ES-SCLC

1L GC/GEJC

1L non-squamous NSCLC

1L squamous NSCLC

Resectable stage II or IIIA NSCLC

1L SCLC and NSCLC

Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy
Solid Tumor

1L/2L GC/GEJC

Tislelizumab + Fruquintinib (VEGFR inhibitor)
Solid Tumor

Advanced GC/GEJC and CRC

Tislelizumab + Lenvatinib
Solid Tumor

1L HCC

Tislelizumab + Ociperlimab (anti-TIGIT)
Solid Tumor

1L PD-L1 high advanced NSCLC

2L PD-L1+ advanced ESCC

2L+ cervical cancer

Advanced solid tumors

Tislelizumab + Sitravatinib (multikinase inhibitor)
Solid Tumor

Advanced GC/GEJC/HCC

Advanced solid tumors

Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)
Solid Tumor

Advanced solid tumors

Zanidatamab (anti-HER2 bispecific antibody)
Solid Tumor

2L+ HER2+ BTC

Zanidatamab + Chemotherapy +/- Tislelizumab
Solid Tumor

1L HER2+ BC and 1L HER2+ GC/GEJC

Australia
Australia / China
Australia / US
China
China / S. Korea
China / S. Korea / Taiwan
China / Taiwan / Thailand
Japan
S. Korea / Taiwan
S. Korea / US
Spain / US
Switzerland / US
Taiwan
United States
Worldwide